Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
541 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00263588 | Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer | completed | Phase 2 | 242 | Novartis PharmaceuticalsINDUSTRY | 17 | Dec 12, 2019 | clinicaltrials |
| NCT01197560 | Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) | completed | Phase 2 / Phase 3 | 111 | CelgeneINDUSTRY | 9 | Nov 25, 2019 | clinicaltrials |
| NCT00463385 |
| A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia |
| completed |
| Phase 2 |
| 88 |
| CelgeneINDUSTRY |
| 5 |
| Nov 20, 2019 |
| clinicaltrials |
| NCT01816594 | NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer(NeoPHOEBE) | completed | Phase 2 | 50 | Novartis PharmaceuticalsINDUSTRY | 4 | Nov 14, 2019 | clinicaltrials |
| NCT01392079 | Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine | completed | Phase 2 | 135 | University of UlmOTHER | 3 | Oct 24, 2019 | clinicaltrials |
| NCT01251536 | Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer(Everest2) | completed | Phase 2 | 108 | Universitaire Ziekenhuizen KU LeuvenOTHER | 5 | Oct 11, 2019 | clinicaltrials |
| NCT00709995 | A Study for Participants With Metastatic Renal Cell Carcinoma | completed | Phase 2 | 17 | Eli Lilly and CompanyINDUSTRY | 4 | Sep 30, 2019 | clinicaltrials |
| NCT02119026 | Efficacy And Safety Of Xeliri + Avastin Followed By Xelox + Avastin Or Reverse Sequence In Metastatic Colorectal Cancer(PASSION) | completed | Phase 2 | 120 | Prof. Dr. Werner ScheithauerOTHER | 1 | Sep 25, 2019 | clinicaltrials |
| NCT01088737 | Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna | unknown | Phase 2 / Phase 3 | 60 | Medical University of GrazOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT02012192 | GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer | terminated | Phase 1 / Phase 2 | 133 | Medical University InnsbruckOTHER | 4 | Aug 13, 2019 | clinicaltrials |
| NCT02931929 | MITIGATE-NeoBOM: A Study to Evaluate 68Ga- NeoBOMB1 in Patients With Advanced TKI-treated GIST Using PET/CT | completed | Phase 1 / Phase 2 | 9 | Medical University InnsbruckOTHER | 1 | Jul 19, 2019 | clinicaltrials |
| NCT02447666 | Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML) | completed | Phase 2 | 28 | CelgeneINDUSTRY | 13 | Jul 11, 2019 | clinicaltrials |
| NCT01367665 | STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma | completed | Phase 2 | 1,232 | Hoffmann-La RocheINDUSTRY | 37 | Jun 6, 2019 | clinicaltrials |
| NCT01005199 | Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer | completed | Phase 2 | 106 | Swiss Cancer InstituteOTHER | 3 | May 15, 2019 | clinicaltrials |
| NCT02231762 | Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET(SONNET) | completed | Phase 2 | 57 | IpsenINDUSTRY | 2 | May 6, 2019 | clinicaltrials |
| NCT03070574 | Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome(MesaCAPP) | terminated | Phase 2 | 8 | Christoph GascheOTHER | 6 | Apr 18, 2019 | clinicaltrials |
| NCT02083653 | Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer | completed | Phase 2 | 254 | Symphogen A/SINDUSTRY | 10 | Apr 16, 2019 | clinicaltrials |
| NCT02632786 | The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis(PRONTO) | completed | Phase 2 | 129 | Prothena Biosciences Ltd.INDUSTRY | 10 | Apr 5, 2019 | clinicaltrials |
| NCT03154047 | Study in Subjects With Light Chain (AL) Amyloidosis | terminated | Phase 2 | 80 | Prothena Biosciences Ltd.INDUSTRY | 10 | Mar 26, 2019 | clinicaltrials |
| NCT01907100 | Nintedanib (BIBF 1120) in Mesothelioma | terminated | Phase 2 / Phase 3 | 545 | Boehringer IngelheimINDUSTRY | 27 | Mar 18, 2019 | clinicaltrials |
| NCT01164189 | Bevacizumab in Recurrent Grade II and III Glioma(TAVAREC) | completed | Phase 2 | 155 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 8 | Feb 28, 2019 | clinicaltrials |
| NCT01881230 | Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)(tnAcity) | completed | Phase 2 / Phase 3 | 191 | CelgeneINDUSTRY | 12 | Feb 21, 2019 | clinicaltrials |
| NCT02129556 | Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer(PANACEA) | completed | Phase 1 / Phase 2 | 58 | ETOP IBCSG Partners FoundationNETWORK | 5 | Feb 15, 2019 | clinicaltrials |
| NCT01523639 | A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis(G-LUCAS) | terminated | Phase 2 | 8 | Austrian Breast & Colorectal Cancer Study GroupNETWORK | 1 | Dec 19, 2018 | clinicaltrials |
| NCT02044822 | Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion | terminated | Phase 2 | 102 | Gilead SciencesINDUSTRY | 14 | Nov 19, 2018 | clinicaltrials |
| NCT00782067 | Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia | completed | Phase 2 | 116 | Novartis PharmaceuticalsINDUSTRY | 12 | Nov 15, 2018 | clinicaltrials |
| NCT02200081 | Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC(IMPULSE) | completed | Phase 2 | 103 | Mologen AGINDUSTRY | 4 | Nov 15, 2018 | clinicaltrials |
| NCT01891227 | Capecitabine + Bendamustine in Women With Pretreated Locally Advanced or Metastatic Her2-negative Breast Cancer(MBC-6) | completed | Phase 2 | 40 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Nov 7, 2018 | clinicaltrials |
| NCT00454779 | PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response | completed | Phase 2 | 113 | AmgenINDUSTRY | 9 | Oct 17, 2018 | clinicaltrials |
| NCT03000452 | A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)(FUSION-MM-005) | completed | Phase 2 | 18 | CelgeneINDUSTRY | 6 | Oct 16, 2018 | clinicaltrials |
| NCT02181634 | Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma(PrE0204) | completed | Phase 2 | 74 | PrECOG, LLC.OTHER | 2 | Oct 3, 2018 | clinicaltrials |
| NCT01923168 | Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women | completed | Phase 2 | 340 | Novartis PharmaceuticalsINDUSTRY | 17 | Sep 14, 2018 | clinicaltrials |
| NCT00777101 | Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer | completed | Phase 2 | 233 | Puma Biotechnology, Inc.INDUSTRY | 31 | Aug 9, 2018 | clinicaltrials |
| NCT00074087 | Liposomal Doxorubicin in Treating Patients With Stage IIB, Stage IVA, or Stage IVB Recurrent or Refractory Mycosis Fungoides | completed | Phase 2 | 49 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | Jul 9, 2018 | clinicaltrials |
| NCT02273973 | A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI) | completed | Phase 2 | 334 | Genentech, Inc.INDUSTRY | 22 | May 21, 2018 | clinicaltrials |
| NCT02054884 | F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma | terminated | Phase 2 | 13 | Philogen S.p.A.INDUSTRY | 6 | May 18, 2018 | clinicaltrials |
| NCT00275015 | Cyclophosphamide and Total Body Irradiation in Treating Patients Who Are Undergoing an Autologous Peripheral Stem Cell Transplant For Chronic Lymphocytic Leukemia | completed | Phase 2 | 169 | German CLL Study GroupOTHER | 2 | May 11, 2018 | clinicaltrials |
| NCT00278213 | Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia | completed | Phase 2 | 17 | German CLL Study GroupOTHER | 2 | May 11, 2018 | clinicaltrials |
| NCT01860638 | A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma | completed | Phase 2 | 296 | Hoffmann-La RocheINDUSTRY | 15 | Apr 30, 2018 | clinicaltrials |
| NCT00111839 | Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer | completed | Phase 2 | 150 | EMD SeronoINDUSTRY | 3 | Apr 6, 2018 | clinicaltrials |
| NCT01462513 | L-BLP25 in Patients With Colorectal Carcinoma After Curative Resection of Hepatic Metastases(LICC) | completed | Phase 2 | 122 | Prof. Dr. Carl SchimanskiOTHER | 2 | Feb 13, 2018 | clinicaltrials |
| NCT01193699 | Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera(PEGINVERA) | completed | Phase 1 / Phase 2 | 24 | AOP Orphan Pharmaceuticals AGINDUSTRY | 1 | Jan 30, 2018 | clinicaltrials |
| NCT00565981 | A Pilot Trial With Subcutaneous Alemtuzumab and Oral Fludarabinephosphate for the Determination of Safety, Efficacy and Molecular Profiling for the Prediction of Response | completed | Phase 2 | 10 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Dec 7, 2017 | clinicaltrials |
| NCT01611259 | Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue | completed | Phase 2 | 50 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT01004003 | Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 2 | 125 | Boehringer IngelheimINDUSTRY | 8 | Oct 26, 2017 | clinicaltrials |
| NCT01815840 | A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas | completed | Phase 2 | 229 | Hoffmann-La RocheINDUSTRY | 10 | Sep 28, 2017 | clinicaltrials |
| NCT00151242 | Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 2 / Phase 3 | 920 | University of UlmOTHER | 2 | Sep 20, 2017 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials